Brought to you by 
Daiichi, Heptares join forces to discover GPCR pain compounds
20 Mar 2017
Executive Summary
Daiichi Sankyo Co. Ltd. will collaborate with Sosei Group Corp.'s Heptares Therapeutics Ltd. on a single Heptares-discovered G protein-coupled receptor (GPCR) Daiichi selects and from which the Top Japanese Pharma company will develop small-molecule pain candidates.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daiichi, Heptares join forces to discover GPCR pain compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice